HC Wainwright Reaffirms “Buy” Rating for Syros Pharmaceuticals (NASDAQ:SYRS)

HC Wainwright reissued their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Wednesday, Benzinga reports. The brokerage currently has a $15.00 price target on the stock.

Other equities research analysts have also issued reports about the company. Piper Sandler reissued an overweight rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday, April 3rd. StockNews.com raised shares of Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, May 15th.

Syros Pharmaceuticals Price Performance

SYRS stock opened at $5.16 on Wednesday. Syros Pharmaceuticals has a 52-week low of $2.09 and a 52-week high of $8.17. The company has a quick ratio of 3.01, a current ratio of 3.01 and a debt-to-equity ratio of 1.97. The company has a market capitalization of $137.93 million, a PE ratio of -1.03 and a beta of 1.70. The stock’s 50 day moving average is $5.30 and its two-hundred day moving average is $6.07.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 395.36%. During the same quarter in the prior year, the business posted ($0.85) EPS. Analysts predict that Syros Pharmaceuticals will post -3.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in Syros Pharmaceuticals during the 1st quarter valued at $64,000. Acadian Asset Management LLC acquired a new position in Syros Pharmaceuticals during the first quarter worth about $91,000. Assenagon Asset Management S.A. raised its holdings in shares of Syros Pharmaceuticals by 576.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 169,999 shares of the company’s stock worth $909,000 after purchasing an additional 144,869 shares in the last quarter. Opaleye Management Inc. bought a new position in shares of Syros Pharmaceuticals in the fourth quarter valued at $2,799,000. Finally, Kennedy Capital Management LLC purchased a new stake in shares of Syros Pharmaceuticals during the first quarter valued at $2,166,000. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.